Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: Prevalence and survival-an analysis of data from the ERA-EDTA Registry

Edwin M. Spithoven, Anneke Kramer, Esther Meijer, Bjarne Orskov, Christoph Wanner, Jose M. Abad, Nuria Areste, Ramon Alonso de la Torre, Fergus Caskey, Cecile Couchoud, Patrik Finne, James Heaf, Andries Hoitsma, Johan de Meester, Julio Pascual, Maurizio Postorino, Pietro Ravani, Oscar Zurriaga, Kitty J. Jager, Ron T. Gansevoort*ERA-EDTA Registry, EuroCYST Consortium, WGIKD

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

147 Citations (Scopus)


Background. Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common renal disease requiring renal replacement therapy (RRT). Still, there are few epidemiological data on the prevalence of, and survival on RRT for ADPKD.

Methods. This study used data from the ERA-EDTA Registry on RRT prevalence and survival on RRT in 12 European countries with 208 million inhabitants. We studied four 5-year periods (1991-2010). Survival analysis was performed by the Kaplan-Meier method and by Cox proportional hazards regression.

Results. From the first to the last study period, the prevalence of RRT for ADPKD increased from 56.8 to 91.1 per million population (pmp). The percentage of prevalent RRT patients with ADPKD remained fairly stable at 9.8%. Two-year survival of ADPKD patients on RRT (adjusted for age, sex and country) increased significantly from 89.0 to 92.8%, and was higher than for non-ADPKD subjects. Improved survival was noted for all RRT modalities: haemodialysis [adjusted hazard ratio for mortality during the last versus first time period 0.75 (95% confidence interval 0.61-0.91), peritoneal dialysis 0.55 (0.38-0.80) and transplantation 0.52 (0.32-0.74)]. Cardiovascular mortality as a proportion of total mortality on RRT decreased more in ADPKD patients (from 53 to 29%), than in non-ADPKD patients (from 44 to 35%). Of note, the incidence rate of RRT for ADPKD remained relatively stable at 7.6 versus 8.3 pmp from the first to the last study period, which will be discussed in detail in a separate study.

Conclusions. In ADPKD patients on RRT, survival has improved markedly, especially due to a decrease in cardiovascular mortality. This has led to a considerable increase in the number of ADPKD patients being treated with RRT.

Original languageEnglish
Pages (from-to)iv15–iv25
Number of pages11
JournalNephrology, Dialysis, Transplantation
Issue numbersuppl_4
Publication statusPublished - Sep-2014


  • epidemiology
  • prevalence
  • survival
  • renal replacement therapy

Cite this